(Q45749250)

15 December 2017

title

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy (English)

1 reference

15 December 2017

1 reference

1 reference

M Tsiang

1

1 reference

15 December 2017

J F Rooney

series ordinal

2

1 reference

15 December 2017

J J Toole

series ordinal

3

1 reference

15 December 2017

C S Gibbs

series ordinal

4

1 reference

15 December 2017

language of work or name

English

0 references

publication date

1 June 1999

1 reference

15 December 2017

published in

Hepatology

1 reference

15 December 2017

volume

29

1 reference

15 December 2017

issue

6

1 reference

15 December 2017

page(s)

1863-1869

1 reference

15 December 2017

Hepatitis B virus infection

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

Population dynamics of immune responses to persistent viruses.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

Human immunodeficiency virus drug therapy and virus load.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

The dynamics of hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

Dynamics of hepatitis B virus infection in vivo

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

Virus dynamics and drug therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

A novel selective broad-spectrum anti-DNA virus agent

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

Evolution of hepatitis C virus quasispecies in mothers and infants infected through mother-to-infant transmission

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

The problem of antiviral therapy for chronic hepadnavirus infections

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290626

7 January 2021

Identifiers

DOI

10.1002/HEP.510290626

1 reference

15 December 2017

PubMed ID

10347131

1 reference

15 December 2017